



Texas Standard Prior Authorization Form Addendum

Molina Healthcare of Texas SGLT2 Inhibitor- Combination Agents (Medicaid)

This fax machine is located in a secure location as required by HIPAA Regulations. Complete / Review information, sign, and date. Fax signed forms to Molina Pharmacy Prior Authorization Department at **1-888-487-9251**. Please contact Molina Pharmacy Prior Authorization Department at **1-855-322-4080** with questions regarding the prior authorization process. When conditions are met, we will authorize the coverage of SGLT2 Inhibitor-Combination (Medicaid).

Drug Name (select from list of drugs shown / provide drug information)		
INVOKAMET	INVOKAMET XR	SEGLUROMET
SYNJARDY	SYNJARDY XR	XIGDUO XR

Patient Information	
Patient Name:	
Patient ID:	
Patient DOB:	

Prescribing Physician	
Physician Name:	
Physician Phone:	
Physician Fax:	
Physician Address:	
City, State, Zip:	

Diagnosis:	ICD Code:
Directions for administration:	

*****Please include all relevant clinical notes, lab work, medication history and any other applicable documentation.**

Please circle the appropriate answer for each question.

- Is the requested drug required per court order? (court order required) Y N
If the answer to this question is yes, approved for 365 days.
If the answer to this question is no, go to question 2.
- Is the patient 18 years of age or older? Y N
If the answer to this question is yes, go to question 3.
If the answer to this question is no, denied.
- Does the patient have a diagnosis of type 2 diabetes in the last 730 days? Y N
If the answer to this question is yes, go to question 4.
If the answer to this question is no, denied.
- Does the patient have a diagnosis of hepatic impairment in the last 365 days? Y N
If the answer to this question is yes, denied.
If the answer to this question is no, go to question 5.

- | | |
|--|-----------------|
| <p>5. Does the patient have a diagnosis of severe renal impairment (eGFR less than 30 milliliters per minute per 1.73 meters squared), end stage renal disease (ESRD) or dialysis in the last 365 days?
 <i>If the answer to this question is yes, denied.</i>
 <i>If the answer to this question is no, go to question 6.</i></p> | <p>Y N</p> |
| <p>6. Is the daily dose less than or equal to 2 tablets daily?
 <i>If the answer to this question is yes, go to question 7.</i>
 <i>If the answer to this question is no, denied.</i></p> | <p>Y N</p> |
| <p>7. Is the request for a non-preferred drug?
 <i>If the answer to this question is yes, go to question 8.</i>
 <i>If the answer to this question is no, approved for 365 days.</i></p> | <p>Y N</p> |
| <p>8. Has the patient failed a 14-day treatment trial with at least 1 preferred agent within the last 180 days?
 <i>If the answer to this question is yes, approved for 365 days.</i>
 <i>If the answer to this question is no, go to question 9.</i></p> | <p>Y N</p> |
| <p>9. Is there a documented allergy or contraindication to preferred agents in this class?
 <i>If the answer to this question is yes, approved for 365 days.</i>
 <i>If the answer to this question is no, go to question 10.</i></p> | <p>Y N</p> |
| <p>10. Is the drug necessary for treatment of stage-4 advanced metastatic cancer and associated conditions?
 <i>If the answer to this question is yes, approved for 365 days.</i>
 <i>If the answer to this question is no, denied.</i></p> | <p>Y N</p> |

Comments:

I affirm that the information given on this form is true and accurate as of this date.

 Prescriber (or Authorized) Signature

 Date